Our latest infographic breaks down a critical, but under-discussed, implication of the Medicare drug price negotiations: the risk to orphan medicines. While the IRA aims to lower the cost of some therapies, its structure may unintentionally discourage biopharma companies from... View More
This ISPOR Europe 2024 panel report explores pricing and reimbursement (P&R) of multiple medicines in Europe. Work has culminated from the panellists and audience of ~800 participants, where they discussed key challenges and forward-looking solutions for multi-indication products. The insights... View More
In recognition of Rare Disease Day 2025, we turn our attention to EU Joint Clinical Assessment (JCA), to explore the potential impact of JCA across three key dimensions important to sustaining investment and launch of new rare disease treatments in... View More
In this report, explore six themes Dolon believes will impact pricing and access success for rare disease and oncology medicines in 2025. Theme 1: Rising pricing tension Theme 2: Protectionist Policies Theme 3: GLP-1 Wave Theme 4: Oncology Crowding Theme... View More
EU Joint Clinical Assessment (JCA) has the potential to transform the evaluation of medicines in Europe, including orphan drugs. While there’s hope that JCAs will streamline fragmented processes and improve patient access, the road ahead is far from simple. Concerns... View More
Willingness to pay for new medicines has steadily declined in real terms in countries that incorporate cost-effectiveness thresholds in their pricing and reimbursement (P&R) processes. Nations such as the UK, Australia, Canada, and Sweden have not adjusted their thresholds for... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More